Marketing Partnerships

Coramed Technologies has targeted several new markets for the CORA™ system, a new generation of hemostasis monitoring. The innovative technology will not only be able to assist in identifying a patient’s risk of heart attack or stroke, but also provide guidance in selecting appropriate therapies. This will offer physicians and patients extraordinary advantages over competitive systems, as well as rich partner opportunities.

Coramed received FDA marketing clearance of initial devices incorporating CORA technology in 2015.  We are now seeking distribution and marketing partners.

Contact us to discuss potential opportunities.


The CORA system can predict risk of heart attack or stroke for a wide range of populations.